

# Instil Bio Corporate Presentation

September 2024

The logo for InstilBio, featuring the word "InstilBio" in a white, sans-serif font. The "i" in "Instil" has a dot above it, and the "i" in "Bio" has a dot above it. The "B" is significantly larger than the other letters. A thin, light blue diagonal line runs across the bottom right of the slide, passing behind the logo.


InstilBio

Nasdaq: TIL | [www.instilbio.com](http://www.instilbio.com)

# Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “expected,” “exploring,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the license and collaboration agreement with ImmuneOnco, the therapeutic potential of SYN-2510 and SYN-27M, our global development strategy for SYN2510 and SYN-27M, clinical development of SYN-2510 and SYN-27M, including the timing, scope and designs of clinical studies, and the generation of clinical data for SYN-2510 and SYN-27M and the timing thereof, regulatory submissions, including IND submissions and clearances, interactions and approvals and the timing thereof; concerning or implying our ability to acquire and develop new product candidates; our research, development and regulatory plans for our product candidates; our expectations regarding our capital position, resources, and balance sheet and the lease of our U.S. manufacturing facility with respect thereto, and the potential impact thereof on development of any product candidates; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with in-licensing or acquiring additional product candidates and clinical trial collaborations; the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for manufacturing and generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully initiating, enrolling, completing and reporting data from clinical studies, particularly collaborator-led clinical trials, as well as the risks that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials and that our product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, and other factors, which could materially and adversely affect our business and operations; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process for product candidates across multiple indications and multiple regulatory authorities; the impact of product candidates that may compete with those that we develop; and the sufficiency of our cash resources; and other risks and uncertainties affecting us and our plans and development programs, including those discussed in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC, as well as our other filings with the SEC. Additional information will be made available in other filings that we make from time to time with the SEC. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

# Global SYN-2510/IMM2510 Development Strategy




\*Based on IND submission in late 2024

\*\*Assumes positive Phase 2 data and alignment with regulatory agencies on registrational trial

\*\*\*If required, based on discussions with regulatory authorities


TNBC: triple-negative breast cancer; NSCLC: non-small cell lung cancer

# Key features of SYN-2510, bispecific PD-L1xVEGF antibody



## Differentiated design

- PD-L1 targeting
- VEGF trap
- ADCC-enhanced



## Intellectual Property

- Composition of matter coverage into 2040 (US)



## Collaboration with ImmuneOnco (HKEX:1541)

- In China, opportunity to leverage proof-of-concept data generation and accelerate clinical development





## Combination of validated oncology mechanisms

- PD-L1 blockade
- VEGF blockade
- PD-(L)1xVEGF bispecifics have demonstrated superiority over standard of care and/or compelling clinical activity


# Key Competitor Landscape

|                   | SYN-2510   | BNT327 (Biotheus / BioNTech)                                 | Ivonescimab (Akeso / Summit)   |
|-------------------|--|--|--|
| VEGF binding      | VEGF-A, VEGF-B, PLGF   | VEGF-A   | VEGF-A   |
| PD-1 or PD-L1     | PD-L1  | PD-L1  | PD-1   |
| ADCC              | Enhanced ADCC  | None   | None   |
| Key clinical data | Multiple responses in patients w/ prior PD-1 in Phase 1a trial | 1L NSCLC*: 47% ORR<br>1L TNBC*: 79% ORR<br>2L SCLC*: 61% ORR | Superiority over Keytruda® in 1L NSCLC**<br>Approved in 2L EGFRm NSCLC |



# PD-1xVEGF bispecific ivonescimab has demonstrated superiority vs Keytruda®

- Ivonescimab (PD-1xVEGF bispecific) monotherapy demonstrated stat. sig. improvement in PFS vs. Keytruda® monotherapy in 1L NSCLC
- **First randomized Phase 3 trial reported of a regimen outperforming standard-of-care Keytruda®**






# PD-L1xVEGF bispecific BNT327 has demonstrated clinical activity in multiple solid tumors


## Phase 1/2 study (NCT05918445): efficacy signals in 1L NSCLC

Wu, C. et al., ASCO 2024, Poster #8533




## Phase 2 (NCT05879068): clinical activity in combination with paclitaxel in 2L SCLC

Ying Cheng et al., ESMO 2023, Poster#1992P



## Phase 2 (NCT05918133): clinical activity in combination with nab-paclitaxel in 1L TNBC

Jiong Wu et al., SABCS 2023, Poster #PS08-06




- BNT327 has demonstrated “Strong single compound activity, and high ORRs observed in combination with CTx in various indications”

# SYN-2510 achieved responses in NSCLC patients with prior PD-1 inhibitor in Phase 1a


## Squamous NSCLC

Treatment of duration for anti-tumor therapies and best of response



## Squamous NSCLC

Treatment of duration for anti-tumor therapies and best of response




**SYN-2510 completed dose escalation up to 20 mg/kg Q2W with a manageable safety profile and no observed dose-limiting toxicities (DLT)**



# SYN-2510 achieved multiple PR and SD in dose escalation

## Change in Target Lesion Tumor Size



# ImmuneOnco collaboration provides opportunity to accelerate global clinical development of SYN-2510

- Collaboration with ImmuneOnco (HKEX:1541), a Hong Kong-listed biotech developing SYN-2510/IMM2510 in China
- Potential opportunities to utilize ImmuneOnco's clinical dataset:
  - Proof-of-concept in tumor types and subpopulations
  - Supporting FDA regulatory filings
  - As part of global trial to support potential registrational filings
- SynBioTx, Inc.\* has exclusive rights for SYN-2510 outside of Greater China and may collaborate with ImmuneOnco for China development of SYN-2510 to expand enrollment in indications of interest, explore novel combinations, and generate data to support potential future global clinical trials

# Recent Corporate Update ([Q2'24 Earnings PR](#))

## Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 13, 2024 at 5:01 PM EDT

- **Executed lease of our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP:** In July 2024, Instil reported the execution of a lease of its U.S. cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP. Under the terms of the agreement, initial base rent is greater than \$7.5 million annually, and escalates at 3% per annum, with the tenant also required to pay certain operating expenses and tax expenses, subject to certain rent abatement in the first year of the 15-year lease term.

- **Cash runway expected beyond 2026.**

### Second Quarter 2024 Financial and Operating Results:

As of June 30, 2024, Instil had cash, cash equivalents, marketable securities and long-term investments of \$152.6 million,

# Thank you

Investor Relations

(972) 499-3350

[investorrelations@instilbio.com](mailto:investorrelations@instilbio.com)

InstilBio